Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients

Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Larissa Sgaria PachecoElizete Keitel

Abstract

Currently, there is no specific immunosuppressive protocol for hepatitis C (HCV)-positive renal transplants recipients. Thus, the aim of this study was to evaluate the conversion effect to everolimus (EVR) on HCV in adult kidney recipients. This is an exploratory single-center, prospective, randomized, open label controlled trial with renal allograft recipients with HCV-positive serology. Participants were randomized for conversion to EVR or maintenance of calcineurin inhibitors. Thirty patients were randomized and 28 were followed-up for 12 months (conversion group, Group 1 =15 and control group, Group 2 =13). RT-PCR HCV levels reported in log values were comparable in both groups and among patients in the same group. The statistical analysis showed no interaction effect between time and group (p value G*M= 0.852), overtime intra-groups (p-value M=0.889) and between group (p-value G=0.286). Group 1 showed a higher incidence of dyslipidemia (p=0.03) and proteinuria events (p=0.01), while no difference was observed in the incidence of anemia (p=0.17), new onset of post-transplant diabetes mellitus (p=1.00) or urinary tract infection (p=0.60). The mean eGFR was similar in both groups. Our study did not show viral load decrease af...Continue Reading

References

Mar 27, 2001·Transplantation Proceedings·V MasG de Boccardo
Jul 31, 2001·Transplantation·H U Meier-KriescheB Kaplan
May 13, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Fabrizio FabriziGareth Dulai
Apr 1, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L M KucirkaD L Segev
May 21, 2010·International Immunopharmacology·Doris WagnerFlorian Iberer
Jul 20, 2011·Nature·Herb Brody
May 19, 2012·Clinical Transplantation·Silvia Naomi de Oliveira UeharaMaria Lucia Cardoso Gomes Ferraz
Jan 3, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Homie RazaviRitesh Kumar
Oct 17, 2013·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Amin SolimanMahmoud Soliman
Aug 5, 2014·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·W H LimG R Russ
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun-ichi KawadaHiroshi Kimura
Nov 21, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N KamarL Alric
Nov 26, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D SawinskiR D Bloom
Oct 21, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Julio PascualUNKNOWN Spanish Society of Transplantation Virological and Immune Response Investigation Study Group

❮ Previous
Next ❯

Citations

Feb 26, 2019·Frontiers in Medicine·Andrea AngelettiPaolo Cravedi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Clinical Trials Mentioned

NCT01469884

Software Mentioned

SPPSS

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.